Paris-based obesity care startup Annette has raised €2m to expand clinical support for patients applying GLP-1 weight-loss treatments.
GLP-1 medicines, such as Wegovy and Mounjaro, reduce appetite; Annette states weight can return without supervision, nutrition guidance and emotional support.
The funding will enable Annette to scale its model to tens of thousands of patients in France and across Europe, focapplying on accelerating its clinical companion app, expanding its multidisciplinary medical network and strengthening prevention and education around obesity.
Founded in 2024 by François-Xavier Trancart and Gwen Le Calvez, Annette’s companion app coordinates care through a multidisciplinary team including dietitians, physical activity coaches and psychologists.
Dr Lysiane Jubin, chief medical officer at Annette, stated: “The treatment can reduce appetite. But it does not rewrite eating habits or the relationship with one’s body.
The company states more than 1,000 patients are supported on the platform, claiming average weight loss above clinical trial outcomes, a 90 per cent retention rate at three months and a net promoter score of +70.
The service runs on a €49 monthly subscription.
The round was led by Redstone, Ring Capital and AFI Ventures, with participation from Clover VC and Gfund.
Constantin de Chaudenay, investor at AFI Ventures, stated: “At AFI Ventures, we back entrepreneurs who utilize technology to tackle society’s most pressing challenges.
“Obesity is clearly one of them.
“What builds us particularly enthusiastic about Annette is the rare combination of an ambitious vision, scientific rigour, and a product capable of creating meaningful impact for millions of people.
“We are convinced that the Annette team is building a solution that can truly shift the necessaryle.”
According to the 2024 national OFÉO study, 48.8 per cent of adults in France are overweight or living with obesity, including 18 per cent with obesity, representing nearly 10 million people.
Leave a Reply